{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial on Advances in Esophageal Cancer Management"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, with allocation concealment ensured through sealed envelopes."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were recruited from multiple centers, with eligibility criteria including confirmed EC diagnosis."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either standard care or an enhanced multimodality therapy, including surgery, chemotherapy, radiotherapy, and immunotherapy."
      },
      "Objective": {
        "score": 1,
        "evidence": "The study aimed to assess the impact of multimodality therapy on EC outcomes."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was overall survival, measured over a 5-year period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, with allocation concealment ensured through sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was applied to outcome assessors, patients, and clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention group and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the intervention group and 97 in the control group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group showed a significant improvement in overall survival (hazard ratio = 0.75, 95% CI 0.60 to 0.95; p = 0.02)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 5% of the intervention group and 3% of the control group, with mild severity."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCTXXXXXXX."
      },
      "Funding": {
        "score": 1,
        "evidence": "The trial was funded by [Funding Source]."
      }
    },
    "total_score": 25,
    "max_score": 25
  },
  "model": "gpt-4o"
}